Under the terms of the agreement, Osmetech will use Epidauros’ biomarkers to develop and market assays for its eSensor array systems, the companies said.
Osmetech CEO James White said the agreement gives the company “access to a very strong pipeline” of companion diagnostics for biomarkers and pharmaceutical development. He said the company will use these in its efforts to expand its market position by “linking the drug to the diagnostic.”
Epidauros CEO Michael Lutz said the deal will spur advances not only in the company’s biomarker pipeline, “but also any personalized medicine-related marker our pharma partners may want to develop into molecular diagnostic tests, in particular in the fields of HIV and oncology.”
This is not the first deal between the two companies. In October 2006 Osmetech said it will use Epidauros’ CYP450 2D6 biomarker patent to expand into pharmacogenomics testing.